Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Outset Medical Inc (NQ: OM )

0.5300 +0.0796 (+17.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Outset Medical Inc

< Previous 1 2 3 4 5 6 Next >
Outset Medical Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Outset Medical's (NASDAQ:OM) reported sales totaled $30.55 million. Despite a 10.53% increase in earnings, the company posted a loss of $36.89 million. 
Via Benzinga
83 Biggest Movers From Yesterday
Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results. 
Via Benzinga
Outset Medical More Than Doubles Sales In FY21, Issues Better Than Expected FY22 Outlook
Via Benzinga
Recap: Outset Medical Q4 Earnings
  Outset Medical (NASDAQ:OM) reported its Q4 earnings results on Wednesday, February 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital. 
Via Benzinga
Earnings Scheduled For February 16, 2022
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million. 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
57 Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Inspirato Incorporated (NASDAQ: ISPO) shares climbed 618.2% to close at $92.65 on Thursday, just a few days after the company completed its SPAC merger with Thayer... 
Via Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
Earnings Preview For Outset Medical
Outset Medical (NASDAQ:OM) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Outset... 
Via Benzinga
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-... 
Via Benzinga
Exposures Product Safety
Outset Medical's Tablo Hemodialysis System Cartridge Receives FDA Approval For Manufacturing In North America
The FDA has granted 510(k) clearance for Outset Medical Inc's (NASDAQ: OM) new sterilization method of the cartridge utilized in its Tablo Hemodialysis... 
Via Benzinga
Exposures Product Safety
Outset Medical Inc (OM) Q3 2021 Earnings Call Transcript
OM earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
Outset Medical's Return On Capital Employed Insights
Outset Medical (NASDAQ:OM) brought in sales totaling $25.22 million during Q2 according to data provided by Benzinga Pro.However, earnings decreased 0.78%, resulting in a loss of... 
Via Benzinga
1 Beaten-Down Healthcare Stock to Put on Your Radar
This innovative company is well off its highs and could be worth a look. 
Via The Motley Fool
2 Beaten Down Stocks With 10X Potential
While there's no way to accurately predict the future, these stocks have a chance to produce tremendous returns if things go well. 
Via The Motley Fool
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 18, 2021
Upgrades According to Oppenheimer, the prior rating for The Wendy's Co (NASDAQ: 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday morning, 67 companies achieved new lows for the year. Areas of Significance: Grifols (NASDAQ:GRFS) was the largest firm by market cap to set a new 52-... 
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Monday morning, 34 companies reached new 52-week lows. Things to Consider: Las Vegas Sands (NYSE:LVS) was the largest, in terms of market cap, to set a new 52-week... 
Via Benzinga
After Naming a New CFO, Is This Genetic Diagnostics Company a Buy?
Veracyte appointed Rebecca Chambers, who boasts a wealth of financial executive experience, to the position. 
Via The Motley Fool
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.